Abstract
The article describes a case of late diagnosis of mucocutaneous lymphonodular syndrome (Kawasaki syndrome). At the beginning of the therapy, the child had fever, conjunctivitis, stomatitis, rash, solid swelling of hands and feet, and coronaritis with the development of aneurysms. The article describes the successful use of normal human immunoglobulin for intravenous administration at a dose of 2 g/kg body weight per course in combination with acetylsalicylic acid at the dose of 80 mg/kg per day. After 3 days of treatment, the rash disappeared; limb swelling and symptoms of conjunctivitis significantly reduced; and laboratory parameters of disease activity became normal (erythrocyte sedimentation rate, C-reactive protein concentration). After 3 months, inflammation in the coronary arteries was stopped. After 6 months, a regression of coronary artery aneurysms was recorded. No adverse effects during the immunoglobulin therapy were observed.
Highlights
The article describes a case of late diagnosis of mucocutaneous lymphonodular syndrome (Kawasaki syndrome)
The article describes the successful use of normal human immunoglobulin for intravenous administration at a dose of 2 g/kg body weight per course in combination with acetylsalicylic acid at the dose of 80 mg/kg per day
Что у пациента с длительностью болезни 6 нед назначение иммуноглобулина позволило быстро снизить активность воспаления, а через 3 мес — купировать воспалительные изменения в коронарных артериях, обеспечить регресс аневризм, вернуть ребенка к полноценной жизни
Summary
The article describes a case of late diagnosis of mucocutaneous lymphonodular syndrome (Kawasaki syndrome). Учитывая длительность болезни (6 нед), развитие жизнеугрожающих осложнений (аневризмы коронарных артерий), патогенетическая терапия, согласно международным протоколам лечения синдрома Кавасаки, включала «золотой стандарт»: 10% раствор иммуноглобулина человеческого нормального для внутривенного введения (ВВИГ) в дозе 2 г/кг на курс непрерывно в течение 8–12 ч и ацетилсалициловая кислота в дозе 80 мг/кг в сут с целью противовоспалительного эффекта, с последующим снижением до 5 мг/кг в сут с целью антитромботического эффекта [1].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.